112 related articles for article (PubMed ID: 15167952)
1. [OCTAVE and OPERA: discordance in hypertension therapy?].
Philipp S; Dietz R; Willenbrock R
Herz; 2004 May; 29(3):266-70. PubMed ID: 15167952
[TBL] [Abstract][Full Text] [Related]
2. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
[TBL] [Abstract][Full Text] [Related]
3. [Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
Waeber B
Praxis (Bern 1994); 2000 Apr; 89(16):649-53. PubMed ID: 10823018
[TBL] [Abstract][Full Text] [Related]
4. [Angioedema of the mucous membranes of the upper aerodigestive tract after administration of ACE inhibitors].
Tisch M; Maier H
Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Feb; 32(2):122-3. PubMed ID: 9172718
[TBL] [Abstract][Full Text] [Related]
5. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
6. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
Kostis JB; Packer M; Black HR; Schmieder R; Henry D; Levy E
Am J Hypertens; 2004 Feb; 17(2):103-11. PubMed ID: 14751650
[TBL] [Abstract][Full Text] [Related]
7. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157
[No Abstract] [Full Text] [Related]
8. [130/80 mmHg blood pressure goal. Can that be achieved, and if yes, how?].
Einecke D
MMW Fortschr Med; 1999 Sep; 141(36):60. PubMed ID: 10904605
[No Abstract] [Full Text] [Related]
9. [Compliance of the hypertensive patient in medical practice--analysis of an observation study. 2].
Magometschnigg D; Hitzenberger G
Wien Med Wochenschr; 1997; 147(22):525-8. PubMed ID: 9487621
[TBL] [Abstract][Full Text] [Related]
10. Vasopeptidase inhibitors.
Weber MA
Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
[TBL] [Abstract][Full Text] [Related]
11. Trial logistics, implementation, and conduct of the OCTAVE mega study in Germany. Prospective, randomised, double-blind study to compare the efficacy and tolerability of omapatrilat and enalapril.
Kothny W; Kaaden R; Ludwig P; Chase D; Krekler M
Arzneimittelforschung; 2004; 54(8):474-9. PubMed ID: 15460215
[TBL] [Abstract][Full Text] [Related]
12. Combined neutral endopeptidase inhibitors.
Cuculi F; Erne P
Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
[TBL] [Abstract][Full Text] [Related]
13. Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
Pickering TG
J Clin Hypertens (Greenwich); 2002; 4(5):371-3. PubMed ID: 12368583
[No Abstract] [Full Text] [Related]
14. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension.
Rump LC
Arzneimittelforschung; 2010; 60(3):124-30. PubMed ID: 20422943
[TBL] [Abstract][Full Text] [Related]
15. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril.
Chatzikyrkou C; Haller H; Menne J
Expert Opin Pharmacother; 2009 Aug; 10(11):1833-40. PubMed ID: 19527194
[TBL] [Abstract][Full Text] [Related]
16. [The side effects of angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension].
Babadzhan VD; Lapshina LA; Shkapo VL
Lik Sprava; 2000; (3-4):54-9. PubMed ID: 10921262
[TBL] [Abstract][Full Text] [Related]
17. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
Floras JS
Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
[TBL] [Abstract][Full Text] [Related]
18. Omapatrilat.
Armstrong PW; Lorell BH; Nissen S; Borer J
Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
[No Abstract] [Full Text] [Related]
19. Recent clinical trials with omapatrilat: new developments.
Zanchi A; Maillard M; Burnier M
Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
[TBL] [Abstract][Full Text] [Related]
20. Omapatrilat. Bristol-Myers Squibb.
Tabrizchi R
Curr Opin Investig Drugs; 2001 Oct; 2(10):1414-22. PubMed ID: 11890357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
